section name header

Indications

BEERS REMS


Unlabeled Use:
  • Generalized anxiety disorder.

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: chest pain, palpitations, QT interval prolongation, TORSADES DE POINTES

Derm: sweating, hot flashes, rash

EENT: pharyngitis, rhinitis, tinnitus, visual abnormalities

Endo: diabetes, SIADH

F and E: thirst, hyponatremia

GI: diarrhea, dry mouth, nausea, abdominal pain, altered taste, anorexia, constipation, dyspepsia, flatulence, vomiting

GU: libido, delayed/absent orgasm, ejaculatory delay/failure, erectile dysfunction, menstrual disorders, urinary disorders, urinary frequency

Hemat: BLEEDING

Metab: appetite

MS: back pain, myalgia

Neuro: dizziness, drowsiness, fatigue, headache, insomnia, tremor, agitation, anxiety, confusion, emotional lability, hypertonia, hypoesthesia, impaired concentration, manic reaction, nervousness, paresthesia, SUICIDAL THOUGHTS/BEHAVIORS, twitching, weakness, yawning

Misc: fever

Interactions

Drug-drug:

Drug-Natural Products:

Availability

(Generic available)
  • Tablets: 25 mg; 50 mg; 100 mg
  • Capsules: 25 mg; 50 mg; 100 mg; 150 mg; 200 mg
  • Oral solution (concentrated) (contains 12% alcohol): 20 mg/mL

Route/Dosage

Depression

  • PO (Adults ): 50 mg once daily in the morning or evening initially; after several weeks, may at weekly intervals up to 200 mg/day, depending on response.

Obsessive Compulsive Disorder

  • PO (Adults ): 50 mg once daily in the morning or evening initially; after several weeks, may at weekly intervals up to 200 mg/day, depending on response.
  • PO (Children 13–17 yr): 50 mg once daily.
  • PO (Children 6–12 yr): 25 mg once daily.

Panic Disorder

  • PO (Adults ): 25 mg once daily initially; may after 1 wk to 50 mg once daily.

Post-Traumatic Stress Disorder

  • PO (Adults ): 25 mg once daily for 7 days; then to 50 mg once daily; may then be if needed at intervals of at least 7 days (range 50–200 mg once daily).

Social Anxiety Disorder

  • PO (Adults ): 25 mg once daily initially; then to 50 mg once daily; may be at weekly intervals up to 200 mg/day.

Premenstrual Dysphoric Disorder

  • PO (Adults ): 50 mg/day initially either daily or daily during luteal phase of cycle. Daily dosing may be titrated upward in 50-mg increments at the beginning of a cycle. In luteal phase–only dosing, a 50-mg/day titration step for 3 days at the beginning of each luteal phase dosing period should be used (range 50–150 mg/day).

US Brand Names

Zoloft

Action

  • Inhibits neuronal uptake of serotonin in the CNS, thus potentiating the activity of serotonin. Has little effect on norepinephrine or dopamine.
Therapeutic effects:
  • Antidepressant action.
  • Decreased incidence of panic attacks.
  • Decreased obsessive and compulsive behavior.
  • Decreased feelings of intense fear, helplessness, or horror.
  • Decreased social anxiety.
  • Decrease in premenstrual dysphoria.

Classifications

Therapeutic Classification: antianxiety agents, antidepressants

Pharmacologic Classification: selective serotonin reuptake inhibitors ssris

Pharmacokinetics

Absorption: Appears to be well absorbed after oral administration.

Distribution: Extensively distributed throughout body tissues.

Protein Binding: 98%.

Metabolism/Excretion: Extensively metabolized by the liver; one metabolite has some antidepressant activity; 14% excreted unchanged in feces.

Half-Life: 24 hr.

Time/Action Profile

( antidepressant effect)

ROUTEONSETPEAKDURATION
POwithin 2–4 wkunknownunknown

Patient/Family Teaching

  • Explain purpose and side effects of medication to patient. Advise patient to read Patient Information before starting therapy. Instruct to take as directed. Take missed doses as soon as possible and return to regular dosing schedule. Do not double doses. Do not stop abruptly; may cause dysphoric mood, irritability, agitation, dizziness, sensory disturbances (paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, and hypomania.
  • Instruct patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care provider before taking any new medications, especially St. John’s wort or SAMe.
  • May cause drowsiness or dizziness. Caution patient to avoid driving and other activities requiring alertness until response to the drug is known.
  • Advise patient, family, and caregivers to look for suicidality, especially during early therapy or dose changes. Notify health care provider immediately if thoughts about suicide or dying, attempts to commit suicide, new or worse depression or anxiety, agitation or restlessness, panic attacks, insomnia, new or worse irritability, aggressiveness, acting on dangerous impulses, mania, or other changes in mood or behavior occur.
  • Advise patient and caregivers to immediately notify health care provider if signs/symptoms of serotonin syndrome occur.
  • Advise patient to avoid alcohol or other CNS depressant drugs during therapy and to consult with health care provider before taking other medications and to avoid alcohol or other CNS depressant drugs, including opioids, during therapy.
  • Inform patient that frequent mouth rinses, good oral hygiene, and sugarless gum or candy may minimize dry mouth. If dry mouth persists for >2 wk, consult health care provider regarding use of saliva substitute.
  • Advise patient to wear sunscreen and protective clothing to prevent photosensitivity reactions.
  • Advise patient to notify health care provider if headache, weakness, nausea, anorexia, anxiety, or insomnia persists or if bleeding (bruising, hematoma, epistaxis, petechiae) occurs.
  • Inform patient that sertraline may cause symptoms of sexual dysfunction. In men, ejaculatory delay or failure, libido, and erectile dysfunction may occur. In women, may result in libido and delayed or absent orgasm. Advise patient to notify health care provider if symptoms occur.
  • Emphasize the importance of follow-up exams to monitor progress. Encourage patient participation in psychotherapy to improve coping skills.
  • Rep: Advise women of reproductive potential to notify health care provider immediately if pregnancy is planned or suspected or if breastfeeding. If used during pregnancy, should be tapered during 3rd trimester to avoid neonatal serotonin syndrome. Use in the month before delivery may risk of postpartum hemorrhage. Monitor infants exposed to sertraline for excess sedation, restlessness, agitation, poor feeding, poor weight gain, or respiratory distress; may risk of persistent pulmonary hypertension of the newborn. Inform patient of pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. Register patients by calling the National Pregnancy Registry for Antidepressants at 1-866-961-2388 or online at https://womensmentalhealth.org/research/pregnancyregistry/antidepressants.

Pronunciation

SER-tra-leen

Pill Image

sertraline_195-9196.jpg

Code

NDC Code